...
首页> 外文期刊>Life sciences >Magnetic nanoparticles-loaded liposomes as a novel treatment agent for iron deficiency anemia: In vivo study
【24h】

Magnetic nanoparticles-loaded liposomes as a novel treatment agent for iron deficiency anemia: In vivo study

机译:磁性纳米粒子加载的脂质体作为铁缺乏症的新型处理剂:体内研究

获取原文
获取原文并翻译 | 示例

摘要

Iron deficiency anemia (IDA) is a major worldwide public health problem. This is due to its prevalence among infants, children, adolescents, pregnant and reproductive age women. Ferrous sulfate (FeSO4 ) is the first line therapy for iron IDA. Unfortunately, it is reported that FeSO4 suffers from low absorption rate in the body and itself exhibits severe side effects. Herein, iron oxide magnetic nanoparticles-loaded liposomes (LMNPs) are prepared, characterized and evaluated as a treatment regimen for IDA in Wistar rats (as an animal model). Iron oxide magnetic nanoparticles (MNPs) are prepared and loaded into liposomes using the thin film hydration method. The size of the prepared formulations is in the range 10-100 nm, thus it can avoid the reticular endothelial system (RES), and increased their blood circulation time. For in vivo assessment, thirty-five Wistar rats are divided into 5 groups (n = 7): negative control group, positive control group, and three groups treated with different iron formulations (FeSO4, MNPs and LMNPs). Anemia is induced in the anemic groups by the bleeding method and then treatment started with different iron compounds administrated orally for 13 days. Hematological parameters are followed up during the treatment period. Results indicate that, in the LMNPs group, the hematological parameters turn to normal values and the histopathological structures of the liver, spleen and kidney remain normal. This proves that liposome increases the bioavailability of MNPs. In conclusion, LMNPs demonstrate superiority as a therapeutic regimen for the treatment of IDA among the tested iron formulations.
机译:缺铁性贫血(IDA)是全球主要的公共卫生问题。这是由于婴儿,儿童,青少年,孕妇和生殖年龄妇女的流行。硫酸铁(FeSO4)是铁IDA的第一线疗法。不幸的是,据报道,FeSO4患有身体的低吸收率,并且本身呈现出严重的副作用。在此,制备氧化铁磁性纳米颗粒加载的脂质体(LMNP),其特征和评价为Wistar大鼠IDA的治疗方案(作为动物模型)。使用薄膜水合法制备氧化铁磁性纳米颗粒(MNP)并装入脂质体中。制备的配方的尺寸为10-100nm,因此可以避免网状内皮系统(RES),并增加其血液循环时间。对于体内评估,三十五只Wistar大鼠分为5组(n = 7):阴性对照组,阳性对照组和用不同铁制剂处理的三组(FeSO4,MNP和LMNP)处理。通过出血法在贫血中诱导贫血,然后用不同的铁化合物在口服13天的不同铁化合物开始治疗。在治疗期间随访血液学参数。结果表明,在LMNP组中,血液学参数转向正常值和肝脏,脾肾的组织病理学结构仍然是正常的。这证明脂质体增加了MNP的生物利用度。总之,LMNPS证明了作为治疗测试铁制剂中IDA的治疗方案的优越性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号